| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
213-465 |
DRI_Approach |
denotes |
This study addresses whether Cyclin D1 is indispensable for ErbB2-associated mammary tumor initiation and progression using a breast cancer model in which this cell-cycle regulator can be genetically ablated prior to or after neoplastic transformation. |
| T2 |
466-602 |
DRI_Background |
denotes |
Deficiency in Cyclin D1 delayed tumor onset but did not prevent the occurrence of mammary cancer in mice overexpressing wild-type ErbB2. |
| T3 |
603-820 |
DRI_Outcome |
denotes |
The lack of Cyclin D1 was associated with a compensatory upregulation of Cyclin D3, which explains why the targeted downregulation of Cyclin D1 in established mammary tumors had no effect on cancer cell proliferation. |
| T4 |
821-1013 |
DRI_Approach |
denotes |
Cyclin D1 and D3 are overexpressed in human breast cancer cell lines and primary invasive breast cancers, and Cyclin D3 frequently exceeded the expression of Cyclin D1 in ErbB2-positive cases. |
| T5 |
1014-1163 |
DRI_Outcome |
denotes |
The simultaneous inhibition of both cyclins in mammary tumor cells reduced cancer cell proliferation in vitro and decreased the tumor burden in vivo. |
| T6 |
1164-1336 |
DRI_Outcome |
denotes |
Collectively, the results of this study suggest that only the combined inhibition of Cyclin D1 and D3 might be a suitable strategy for breast cancer prevention and therapy. |
